14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
UPC vs EEIQ: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Universe Pharmaceuticals Inc. (UPC) is the stronger overall head-to-head candidate over EpicQuest Education Group International Limited (EEIQ) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). UPC carries a Unified Composite Score of 41.4/100 (SELL) at $1.08 (N/M Forward P/E, -11.8% operating margin), whereas EEIQ carries 39.2/100 (SELL) at $3.11 (N/M Forward P/E, -47.4% operating margin).
Growth vs. Quality Trade-Off: UPC earns the overall head-to-head edge with a stronger Unified Composite Score (41.4/100 SELL vs. EEIQ 39.2/100 SELL) and 4.56β · 163% Vol risk profile, whereas EEIQ leads top-line expansion (+16.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although UPC compares more favorably head-to-head, both UPC (41.4/100 SELL) and EEIQ (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: UPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile EEIQ trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 25.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UPC vs EEIQ. Trailing 12-month operating profitability (UPC -11.8% vs EEIQ -47.4%) and valuation multiples (UPC N/M vs EEIQ N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Education & Training Services value chain with $5.4M market capitalization and -47.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ UPC vs EEIQ Key Questions & Quantitative Answers
As of Nov 20, 2026, Universe Pharmaceuticals Inc. (UPC) is the stronger overall head-to-head candidate over EpicQuest Education Group International Limited (EEIQ) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). UPC carries a Unified Composite Score of 41.4/100 (SELL) at $1.08 (N/M Forward P/E, -11.8% operating margin), whereas EEIQ carries 39.2/100 (SELL) at $3.11 (N/M Forward P/E, -47.4% operating margin). Growth vs. Quality Trade-Off: UPC earns the overall head-to-head edge with a stronger Unified Composite Score (41.4/100 SELL vs. EEIQ 39.2/100 SELL) and 4.56β · 163% Vol risk profile, whereas EEIQ leads top-line expansion (+16.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although UPC compares more favorably head-to-head, both UPC (41.4/100 SELL) and EEIQ (39.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: UPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.2); meanwhile EEIQ trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 25.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
EEIQ leads the Growth & Scale pillar: UPC posts -1.3% YoY revenue growth and -82.0% YoY earnings growth on $18M TTM revenue (36.5% gross margin, -11.8% operating margin), compared with EEIQ at +16.8% YoY revenue growth and +0.0% YoY earnings growth on $9.8M TTM revenue (62.5% gross margin, -47.4% operating margin). On trailing 12-month operating scale, UPC generates $18M in USD-normalized revenue versus $9.8M for EEIQ. In operating R&D and SG&A reinvestment, UPC deploys 48.3% of Rev ($8.6M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EEIQ.
UPC and EEIQ trade at balanced relative valuation multiples. UPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-9.1% EBITDA margin), whereas EEIQ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (-43.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UPC (-3.5% ROE) versus EEIQ (-46.8% ROE) capital efficiency.
In options market volatility and institutional positioning, UPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.56β · 163% Vol realized risk). By comparison, EEIQ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-1.80β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.